Get the Stockscreener App
0.4939
1.00%
0.0049
After Hours:
.49
-0.0039
-0.79%
Medicus Pharma Ltd stock is traded at $0.4939, with a volume of 1.10M.
It is up +1.00% in the last 24 hours and down -59.52% over the past month.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
See More
Previous Close:
$0.489
Open:
$0.48
24h Volume:
1.10M
Relative Volume:
0.32
Market Cap:
$11.04M
Revenue:
-
Net Income/Loss:
$-22.79M
P/E Ratio:
-0.2935
EPS:
-1.6827
Net Cash Flow:
$-15.11M
1W Performance:
-1.22%
1M Performance:
-59.52%
6M Performance:
-80.08%
1Y Performance:
-84.61%
1-Day Range:
$0.4627
$0.4939
1-Week Range:
$0.4627
$0.532
52-Week Range:
$0.37
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
Name
Medicus Pharma Ltd
Sector
Industry
Phone
610-540-7515
Address
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.4939 | 10.94M | 0 | -22.79M | -15.11M | -1.6827 |
LLY
Lilly Eli Co
|
916.31 | 806.39B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
239.93 | 566.67B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
207.18 | 362.83B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.37 | 287.71B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
187.14 | 288.11B | 58.80B | 10.24B | 8.98B | 3.2788 |
Medicus Pharma Ltd Stock (MDCX) Latest News
Medicus Pharma Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Medicus Pharma (NASDAQ: MDCX) registers 3.245M common shares from warrants - Stock Titan
Medicus Pharma (MDCX) 1.12M shares issuable on warrants — prospectus supplement - Stock Titan
1.397M resale shares registered as Medicus Pharma (NASDAQ: MDCX) shifts S-1 to S-3 - Stock Titan
[POS AM] Medicus Pharma Ltd. S... - Stock Titan
Biotech says 3 in 4 patients may avoid immediate skin cancer surgery - Stock Titan
Medicus Pharma 2025 10-K: Net loss $35.4M, EPS $(2.74) - TradingView
Medicus Pharma to host business update call featuring clinical investigator - MSN
Medicus Pharma on Bloomberg World - Daytona Beach News-Journal
Medicus Pharma to Host Business Update Call Featuring Clinical Investigator - MyChesCo
Medicus Pharma reports phase 2 results for basal cell carcinoma therapy - MSN
Medicus Pharma stock swings after skin cancer treatment results - MSN
Tangible book value per share of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Book value per share of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Whats next for Medicus Pharma Ltd Equity Warrant stock2026 Technical Overview & Precise Swing Trade Alerts - baoquankhu1.vn
Medicus reports phase 2 results for SkinJect basal cell carcinoma study - MSN
Medicus Pharma Ltd expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Analyst Calls: Is Medicus Pharma Ltd exposed to currency risks2026 Price Swings & Technical Entry and Exit Tips - baoquankhu1.vn
Medicus Pharma to host fireside chat on SkinJect trial results By Investing.com - Investing.com South Africa
MDCXW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Medicus Pharma Ltd outperform the market in YEARDividend Hike & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Medicus Pharma prices $7 million share offering - MSN
Medicus Pharma Showcases Strong Phase 2 SkinJect Data Ahead of Fireside Chat - TipRanks
Medicus Pharma to host fireside chat on SkinJect trial results - Investing.com
Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst - ACCESS Newswire
Medicus Pharma (MDCX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Aug Sectors: What is the dividend yield of Medicus Pharma Ltd Equity Warrant2026 Sector Moves & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Medicus Pharma schedules webcast on basal cell carcinoma study By Investing.com - Investing.com Australia
Aug Opening: Is Medicus Pharma Ltd Equity Warrant a speculative investment2026 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Investment Recap: Can Medicus Pharma Ltd sustain its profitabilityTrade Exit Report & Technical Entry and Exit Tips - baoquankhu1.vn
Medicus Pharma to highlight positive Phase 2 SkinJect data during webcast with lead investigator - Proactive financial news
Medicus Pharma Highlights Strong Phase 2 SkinJect Data Ahead of Business Update Call - TipRanks
Medicus Pharma schedules webcast on basal cell carcinoma study - Investing.com
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26 - ChartMill
Medicus Reports Phase 2 Results for SkinJect Basal Cell Carcinoma Study - MyChesCo
Medicus Pharma CEO discusses promising Phase 2 SkinJect resultsICYMI - Proactive financial news
Medicus Pharma Marks Nasdaq Anniversary with Opening Bell Ceremony - The Globe and Mail
Medicus Pharma reports positive phase 2 results for SkinJect skin cancer therapy - MSN
Risk Report: Will Medicus Pharma Ltd outperform the market in YEAR2026 Update & High Accuracy Investment Signals - baoquankhu1.vn
Medicus Pharma receives FDA clearance to begin Phase 2b Teverelix study - MSN
Medicus Pharma to Spotlight AI-Driven Drug Development at Longwood Miami CEO Forum - The Globe and Mail
Medicus Pharma Ltd Stock (MDCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
1.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):